Published in Antiviral Res on August 01, 2002
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J (2011) 1.10
Respiratory syncytial virus vaccine development. Clin Lab Med (2009) 0.98
Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res (2015) 0.89
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet (2010) 12.43
Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis (2013) 7.83
Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet (2004) 7.52
Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis (2006) 6.85
Influenza. Lancet (2003) 6.08
Avian H5N1 influenza in cats. Science (2004) 5.40
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med (2003) 4.86
Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis (2006) 4.34
Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis (2005) 4.33
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis (2009) 3.76
Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis (2002) 3.66
Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis (2009) 3.37
Influenza vaccination of health care workers in hospitals--a review of studies on attitudes and predictors. Vaccine (2009) 2.96
Sudden acute respiratory syndrome. BMJ (2003) 2.68
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis (2010) 2.67
Transparent development of the WHO rapid advice guidelines. PLoS Med (2007) 2.57
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 2.46
Severe acute respiratory syndrome revisited. BMJ (2003) 2.15
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A (2009) 2.08
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine (2003) 2.04
A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses (2007) 1.92
The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS Curr (2009) 1.87
A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine (2009) 1.80
Mechanical stimulation improves tissue-engineered human skeletal muscle. Am J Physiol Cell Physiol (2002) 1.76
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis (2011) 1.66
Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. J Urol (2010) 1.63
Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". Science (2012) 1.58
Another phocine distemper outbreak in Europe. Science (2002) 1.55
Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol (2011) 1.55
Open source clinical science for emerging infections. Lancet Infect Dis (2014) 1.47
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill (2016) 1.46
Genital herpes simplex infections: some therapeutic dilemmas. Sex Transm Dis (2003) 1.42
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther (2009) 1.39
A pre-clinical assessment of an atlas-based automatic segmentation tool for the head and neck. Radiother Oncol (2009) 1.38
DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine (2009) 1.37
Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. J Virol (2004) 1.37
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther (2005) 1.33
The evolution of norovirus, the "gastric flu". PLoS Med (2008) 1.32
Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses (2011) 1.32
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One (2011) 1.31
Global task force for influenza. Nature (2005) 1.31
Influenza among U.K. pilgrims to hajj, 2003. Emerg Infect Dis (2004) 1.29
Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill (2015) 1.28
Transmission of avian influenza viruses to and between humans. J Infect Dis (2005) 1.27
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis (2013) 1.23
Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ (2006) 1.21
Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J Virol (2002) 1.21
Association of respiratory syncytial virus M protein with viral nucleocapsids is mediated by the M2-1 protein. J Virol (2008) 1.21
Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm (2004) 1.21
Interaction between the respiratory syncytial virus G glycoprotein cytoplasmic domain and the matrix protein. J Gen Virol (2005) 1.19
Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine (2011) 1.18
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill (2015) 1.17
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs (2009) 1.17
Feline friend or potential foe? Nature (2006) 1.16
Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells. J Virol (2007) 1.14
Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Allergy Immunol (2003) 1.14
The microbiology of asthma. Nat Rev Microbiol (2012) 1.14
In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother (2002) 1.13
Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis (2013) 1.12
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis (2008) 1.11
Preparing the outbreak assistance laboratory network in the Netherlands for the detection of the influenza virus A(H1N1) variant. J Clin Virol (2009) 1.07
Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein. J Gen Virol (2005) 1.07
Emerging viral infections in a rapidly changing world. Curr Opin Biotechnol (2003) 1.05
Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Dis (2011) 1.03
Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol (2002) 1.01
Near patient testing for influenza in children in primary care: comparison with laboratory test. BMJ (2003) 1.01
A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir Viruses (2009) 1.01
Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011. Emerg Infect Dis (2012) 1.01
Review: interventions to increase influenza vaccination among healthcare workers in hospitals. Influenza Other Respir Viruses (2012) 1.00
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis (2004) 1.00
Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. Emerg Infect Dis (2011) 0.99
Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood (2009) 0.98
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. Euro Surveill (2016) 0.97
Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res (2011) 0.97
Contribution of cytokines to pathology and protection in virus infection. Curr Opin Virol (2011) 0.95
Pandemic risks from bird flu. BMJ (2004) 0.95
A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. MBio (2014) 0.95
Predominance of heterosubtypic IFN-γ-only-secreting effector memory T cells in pandemic H1N1 naive adults. Eur J Immunol (2012) 0.94
Human microbial challenge: the ultimate animal model. Lancet Infect Dis (2012) 0.93
Mitochondria, prostate cancer, and biopsy sampling error. Discov Med (2013) 0.92
Influenza virus resistance to antiviral therapy. Adv Pharmacol (2013) 0.92
Influenza A and B virus attachment to respiratory tract in marine mammals. Emerg Infect Dis (2012) 0.92
Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable - epidemiology, diagnostics and treatment. Crit Rev Microbiol (2012) 0.91
HIV infection and aging of the innate immune system. Sex Health (2011) 0.91
Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis (2004) 0.88
Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine (2008) 0.88
Nucleic acid dipstick test for molecular diagnosis of pandemic H1N1. J Clin Microbiol (2010) 0.87
Pigs, poultry, and pandemic influenza: how zoonotic pathogens threaten human health. Adv Exp Med Biol (2011) 0.87
VII International Symposium on Respiratory Viral Infections. Antivir Ther (2007) 0.87
Guidance on the development and validation of diagnostic tests that depend on nucleic acid amplification and detection. J Clin Virol (2012) 0.87
Identification of serum analytes and metabolites associated with aerobic capacity. Eur J Appl Physiol (2012) 0.86
Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007. Vaccine (2008) 0.86
Personal protective equipment and risk for avian influenza (H7N3). Emerg Infect Dis (2009) 0.86